📁Pharma Team / Shared drive

Maintained by Market Access Strategy. Updated quarterly or on receipt of new approved counter-evidence. Distribution: Market Access team, KAMs, MSLs (for clinical-objection responses).

Purpose

This playbook captures the top payer objections raised in contracting and P&T discussions for Zenvara, along with approved evidence-based responses. The objections are sourced from the past 18 months of contracting interactions, AMCP dossier requests, and competitor decision-impact materials. Use this playbook in payer meetings, P&T preparation, and KAM training; do not freelance off it.

Top 10 objections (by frequency)

1. Budget impact at year 2 is too high.

2. Cost-effectiveness ratio not favorable at the prevailing US value benchmark.

3. Competitor X (pembrolizumab) is established standard of care and lower net cost.

4. Patient population not well differentiated from broader 1L NSCLC.

5. Specialty pharmacy distribution adds friction.

6. Real-world durability evidence not yet mature.

7. Subgroup data for PD-L1-low patients not robust.

8. Q6W dosing is operationally complex for infusion-center scheduling.

9. Patient assistance program is restrictive.

10. Long-term safety data limited to pivotal trial.

Objection 1 — Budget impact at year 2

Frequency: 78% of payer meetings raise this. Underlying concern: payers model a 5-year budget impact (BIM) and the year-2-3 uptake is the largest single driver.

Approved response: Reference BIM v4 (updated Q1 2026 to reflect ZENITH-1 long-term follow-up). BIM v4 incorporates the medical-cost offset from reduced ER visits and reduced inpatient admissions in the Zenvara arm of ZENITH-1; the net BIM at year 2 is $2.40 PMPM versus a comparable comparator of $2.85 PMPM.

Supporting evidence: real-world Optum claims cohort (n=12,400 NSCLC patients) showing 18% reduction in NSCLC-related ER visits and 12% reduction in inpatient days among Zenvara-treated patients vs. comparator cohort. Cohort analysis published in JMCP March 2026.

Objection 2 — Cost-effectiveness ratio

Frequency: 64% of meetings. Underlying concern: ICER per QALY exceeds the $150,000/QALY threshold preferred by many US payers.

Approved response: ZENITH-1 base-case ICER (manufacturer model) is $128,400/QALY when compared to pembrolizumab in the PD-L1≥50% population, within the $100k-$150k/QALY value range. Sensitivity analyses show the result is most sensitive to drug acquisition cost (-12% to +18% with rebate scenarios) and to long-term OS extrapolation method.

ICER (Institute for Clinical and Economic Review) issued a draft evidence report on Zenvara in October 2025 with an overall rating of B+ ("promising but inconclusive") and a value-for-money rating of "intermediate". The HBPB (Health-Benefit Price Benchmark) range published with the draft report is $98,400-$143,200, with our current net price ($93,200) falling within the lower end of that range.

Supporting evidence: ICER Final Evidence Report (December 2025), HEOR cost-effectiveness model v6 (March 2026 refresh).

Objection 3 — Pembrolizumab is established SoC and lower net cost

Frequency: 58% of meetings.

Approved response: Direct head-to-head in ZENITH-1 demonstrates Zenvara superiority on OS (HR 0.78, 95% CI 0.66-0.92, p=0.003) and PFS (HR 0.73, 95% CI 0.62-0.86, p<0.001) versus pembrolizumab in the PD-L1≥50% population. Net cost difference is approximately $8,400 per patient per year (manufacturer modeling at current rebate structure). The patient-level benefit-cost tradeoff is favorable to Zenvara in the indicated population.

Objection 4 — Population differentiation

Frequency: 41% of meetings.

Approved response: Zenvara's indication is specifically PD-L1≥50%, representing approximately 35% of 1L metastatic NSCLC patients. The subgroup analysis from KEYNOTE-189 and KEYNOTE-024 establishes that this is the population where single-agent immunotherapy outperforms combination chemo+IO. Zenvara is the only agent with a positive head-to-head OS outcome vs pembrolizumab in this subgroup.

Objection 5 — Specialty pharmacy distribution

Frequency: 32% of meetings.

Approved response: Zenvara is distributed through specialty pharmacy with 48-hour PA-to-shipment SLA. Three major SPs are credentialed (Accredo, AllianceRx Walgreens, CVS Specialty); plan-of-record SP can be designated at the payer level. Patient assistance program (ZPAP) bridges any specialty pharmacy access friction during PA processing.

Objection 6 — Real-world durability

Frequency: 28% of meetings.

Approved response: ZENITH-1 long-term follow-up will report 5-year OS at ASCO 2026 (LBA, embargo lifts June 2). Interim 4-year OS data shows 38% OS rate vs 25% for pembrolizumab control, consistent with the 24-month primary endpoint trajectory. Real-world durability evidence is being generated through the ZEN-RWD registry (n=1,840 patients enrolled, target 4,000 by Q4 2026); first interim analysis scheduled Q3 2026.

Objection 7 — PD-L1-low subgroup

Frequency: 24% of meetings. (Less common, raised in payer-driven indication-expansion discussions.)

Approved response: Zenvara is not indicated in PD-L1<50%; ZENITH-1 was designed and powered exclusively in the high-expression population. The IMpact-2 trial (Ph3, enrolling) will read out in PD-L1 1-49% in late 2026. Until then, Zenvara discussions in PD-L1-low patients are off-label and not supported.

Objection 8 — Q6W dosing scheduling

Frequency: 22% of meetings.

Approved response: Q6W dosing reduces infusion-center visits by 50% versus Q3W standard. Infusion-center scheduling tool ("Zenvara Scheduler") available to participating practices; integrates with major EHR systems (Epic, Cerner, Athena) for batch-scheduling of Q6W appointments. Patient-level data show 96% on-time dose adherence at the Q6W cadence.

Objection 9 — Patient assistance program

Frequency: 18% of meetings.

Approved response: ZPAP is one of three concentric programs available. Co-pay assistance covers up to $20,000/year for commercial patients. Bridge program covers up to 90 days during PA processing. Foundation-based assistance for uninsured/underinsured patients available through PAN Foundation (annual income cap: $84,400 for 2026).

Objection 10 — Long-term safety

Frequency: 12% of meetings.

Approved response: ZENITH-1 long-term safety follow-up at 48 months shows no new safety signals beyond the labeled adverse events. Grade 3+ AE rate: 14% Zenvara vs 18% pembrolizumab. Treatment-related discontinuation: 6% Zenvara vs 8% pembrolizumab. Phase 4 PMR safety surveillance ongoing through 2028.

Cross-references

2026 US Payer Landscape Brief (1D2…), Evidence Dossier Index (1I8…), HTA Evidence Gap Report (1J4…), MAR-cleared key message bank (Veeva Vault PromoMats).